Anti-TB Treatment and Targeted Therapy: — A Combination That Needs Specialist Coordination

You should not start rifampicin without telling your oncologist first. Rifampicin significantly lowers the blood levels of most targeted therapies, which can make your cancer treatment ineffective. Your oncologist and TB physician need to discuss the situation together — the solution may involve choosing a different TB drug, adjusting how your cancer drug is dosed, or managing the two treatments in a different sequence. That decision belongs to your medical team, not to you.

Rifampicin is by far the most significant. It is the strongest activator of the liver enzymes that break down targeted therapies, and it is also the cornerstone of standard TB treatment in India. Other TB drugs — isoniazid, ethambutol and pyrazinamide — carry far fewer interactions with targeted therapy, though isoniazid has its own interactions with other medicines that your team should review when they see your full medicine list.

Rifabutin, another antibiotic in the rifamycin family, activates the same liver enzymes as rifampicin but to a lesser degree, and it is used in some settings as a less disruptive alternative. Whether it is appropriate for your TB depends on the strain of TB, your treatment history, local resistance patterns, and which cancer drug you are taking. This is a specialist decision that requires your oncologist and a chest physician or infectious disease specialist working together — it is not a switch you can make yourself.

The cancer drug may no longer be working at the concentration your oncologist intended. This does not cause any immediate symptom — you will not feel the interaction as it happens. Over weeks, the consequence can be a loss of disease control that only becomes visible on a scan or through a change in your condition. This is what makes the interaction particularly dangerous: it is silent until something has already gone wrong.

Do not stop either treatment without speaking to your oncologist first. Stopping targeted therapy without medical guidance can allow the cancer to progress. At the same time, inadequately treated TB in someone on cancer treatment can be life-threatening. The right approach is for both your oncologist and your TB physician to know about both conditions and manage them together — not for you to choose between them.

The liver enzyme activation caused by rifampicin does not switch off the moment you stop the drug. According to NCCN drug interaction guidance, the effect can persist for a period after the last dose. Your oncologist will advise on the appropriate interval before your cancer drug can return to its standard dose. Do not make that change yourself or assume it is safe to restart at full dose immediately.

Not necessarily. Some Ayurvedic and herbal preparations used for chest complaints also interact with liver enzymes, and many have not been studied alongside targeted cancer drugs at all. 'Herbal' does not mean free from drug interactions. Tell your oncologist and your TB physician everything you are taking — including supplements, herbal preparations and traditional medicines. They cannot check for interactions they do not know about, so the full list matters.

Both are responsible, and both need to know. Your oncologist is responsible for the safety and dosing of your cancer treatment. Your TB physician is responsible for an effective TB regimen. Neither can manage the interaction safely without information from the other. Ask your oncologist to contact your TB physician directly, or ask both teams to review your complete medicine list together. If that coordination is not happening, ask each team the same question: has the other specialist been told exactly what medicines I am on?